Sanofi: positive analysis data in RSV
(CercleFinance.com) - Sanofi has reported positive results from a pre-specified analysis of pooled data from the pivotal Phase III MELODY trial and Phase IIb trials evaluating the efficacy of nirsevimab against respiratory syncytial virus (RSV).
The healthcare group announces a 79.5% relative risk reduction (compared to placebo) against medically managed lower respiratory tract infections, including hospitalisations, caused by this virus.
Nirsevimab is the first investigational immunisation agent designed to protect all infants for the duration of the RSV season with a single dose, Sanofi says, which is developing the product in collaboration with AstraZeneca.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The healthcare group announces a 79.5% relative risk reduction (compared to placebo) against medically managed lower respiratory tract infections, including hospitalisations, caused by this virus.
Nirsevimab is the first investigational immunisation agent designed to protect all infants for the duration of the RSV season with a single dose, Sanofi says, which is developing the product in collaboration with AstraZeneca.
Copyright (c) 2022 CercleFinance.com. All rights reserved.